FH535

Short Summary : Wnt/B-catenin inhibitor

Category : Stem Cell|Wnt/β-catenin

Purity : 0.9989

CAS Number : 108409-83-2

Formula : C13H10Cl2N2O4S

Molecular Weight : 361.2

SMILE : CC1=C(C=CC(=C1)[N+](=O)[O-])NS(=O)(=O)C2=C(C=CC(=C2)Cl)Cl

Solubility : >36.1mg/mL in DMSO with gentle warming

Storage : Store at -20°C

Description : FH535 is a small molecule inhibitor of Wnt/B-catenin with IC50 values of 15.4M, 10.9M, 9.3M, respectively in LCSC, Huh7, PLC cell lines [1].FH535 can inhibit the growth of colon, lung, and hepatocellular carcinoma line but not normal fibroblasts. It makes FH535 potentially be a promising therapeutic approach for cancer cells. It is reported that FH535 has ability to inhibit growth, migration, and invasion of TN breast cancer cell lines (MDA-MB-231 and HCC38) without affecting adhesive abilities of cells to type I collagen [2]. FH535 is also an inhibitor of peroxisome proliferatorCactivated receptor (PPAR). It plays a role as a dual PPAR and PPAR antagonist that is able to inhibit GRIP1 and -catenin recruitment [3].References:[1] Roberto R. Galuppo, Roberto Gedaly, Paul Angulo, Michael F. et al. FH535 inhibits wnt/-catenin signaling pathway in liver cancer stem cells and HCC cell lines. Hepatology. 2013, October: 466A.[2] Joji Iida, Jesse Dorchak, John R. Lehman, Rebecca Clancy, Chunqing Luo, Yaqin Chen, Stella Somiari, Rachel E. Ellsworth, Hai Hu, Richard J. Mural, Craig D. Shriver. FH535 Inhibited Migration and Growth of Breast Cancer Cells. PLOS ONE. 2012, 7(9): 1-11.[3] Shlomo Handeli and Julian A. Simon. A small-molecule inhibitor of Tcf/-catenin signaling down-regulates PPAR and PPAR activities. Molecular Cancer Therapeutics. 2008, 7:521-529.

Download datasheet